GlassScriptPhysician profile
Arathi R Goldsmith
NPI 1437387404
$8,943.65
in general payments reported to CMS, 2019-2025
36 companies · $2,066 in 2025
The $2,066 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $434 · 2021: $901 · 2022: $1,307 · 2023: $856 · 2024: $2,245 · 2025: $2,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,799 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,799.24 |
| Education | $367.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,493.39 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,238.15 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $754.20 | 2021-2025 | Winlevi, Absorica Ld |
| Amgen INC. | $642.74 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $529.36 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $420.52 | 2019-2025 | |
| Almirall LLC | $386.85 | 2019-2024 | Seysara |
| Dermavant Sciences, INC. | $335.27 | 2023-2024 | Vtama |
| Pfizer INC. | $321.42 | 2019-2025 | |
| Galderma Laboratories, L.P. | $313.99 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $300.64 | 2019-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $263.79 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.18 | 2022-2025 | Spevigo |
| Leo Pharma INC. | $239.98 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $234.33 | 2022-2024 | Sotyktu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $163.46 | 2019-2025 | |
| Celgene Corporation | $157.58 | 2019 | |
| Arcutis Biotherapeutics, INC. | $133.63 | 2023-2025 | Zoryve |
| Medimetriks Pharmaceuticals, INC. | $95.90 | 2024 | Clindacin Etz |
| Incyte Corporation | $74.41 | 2021-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Verrica Pharmaceuticals INC. | $65.16 | 2023-2024 | Ycanth |
| Lilly USA, LLC | $62.93 | 2022-2024 | Ebglyss, Taltz |
| Mayne Pharma Commercial LLC | $62.32 | 2019-2025 | |
| Dermira, INC. | $53.38 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $49.90 | 2020 | |
| Organon LLC | $49.64 | 2025 | Vtama |
| Sandoz INC. | $36.20 | 2019-2020 | |
| Journey Medical Corporation | $24.24 | 2021 | |
| Genentech USA, INC. | $22.07 | 2020 | |
| Epi Health, LLC | $17.73 | 2021 | |
| Encore Dermatology INC. | $16.49 | 2019 | |
| Tactile Systems Technology INC | $16.49 | 2021 | |
| Cipher Pharmaceuticals US LLC | $13.95 | 2025 | Spinosad, Natroba |
| Pinnacle, INC | $12.74 | 2020 | |
| Mylan Pharmaceuticals INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arathi Goldsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.